# Ipamorelin Dosage in Research Context: Doses, Routes, Half-Life

> Ipamorelin dosage, research context only: the doses and routes studied in humans, rats, and ferrets, the ~2h half-life, and why the CJC-1295 stack has no human dosing basis. No recommendations.

What was administered, to which species, by which route — third person only. No human dosing recommendation appears on this page.

## Read this first

This page describes ipamorelin dosage the way the studies describe it — what was given, to which animal or which trial population, by which route. It is not a protocol. It contains no recommendation for any person to take anything. There is no approved human dose, because ipamorelin is not an approved drug. The community "stack" routines that pair it with CJC-1295 have no peer-reviewed human dosing basis and are described here only as what they are: anecdote. The one figure worth carrying away is the half-life — about two hours in people — because it explains the single short GH pulse the compound produces. Doses below are in the units the original papers used (nmol/kg, μg/day, mg/kg); they are records of experiments, not instructions.

## Doses studied, by species

The published doses span human trials and rodent or ferret models:

- **Human PK/PD (healthy male volunteers):** 4.21, 14.02, 42.13, 84.27, 140.45 nmol/kg, IV over 15 minutes, single doses [2].
- **Human Phase 2 ileus RCT:** 0.03 mg/kg IV twice daily, postoperative days 1-7 or until discharge [3].
- **Rat bone-growth study:** 18, 90, 450 μg/day subcutaneous, divided three times daily, 15 days [4].
- **Mouse (STZ diabetic) PK:** single IV injection (dose not specified in the abstract) [7].
- **Ferret cachexia study (2024):** 1-3 mg/kg intraperitoneal [5].

These span IV, subcutaneous, and intraperitoneal routes and acute-to-15-day durations. None establishes a safe or effective human dose; the human trial that tested one was negative [3].

## Routes and bioavailability studied

Ipamorelin has been studied by several routes. Intravenous dominates the human PK and clinical work and the rodent efficacy studies [2][3]. Subcutaneous is the route in the rodent bone and body-composition studies — and the dominant route in off-label community use, which has no published human safety or PK data [4]. Intranasal has been examined in rodent PK (around 20% bioavailability). Intraperitoneal appears in rodent and ferret efficacy work [5]. Oral bioavailability applies only to engineered ipamorelin-derived analogs (around 10% in dog); ipamorelin itself is not orally bioavailable. Route matters here because the compound's whole effect is a single timed GH pulse, and absorption kinetics shape that pulse.

## Half-life and the single pulse

Terminal half-life in healthy human volunteers is approximately 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. The GH response is not sustained — it is one discrete pulse peaking near 40 minutes after dosing [2]. In rats, plasma clearance runs roughly 5-fold lower than GHRP-6. The short half-life and single-pulse profile are why community routines time injections to specific windows; the full pharmacokinetic read is on the [half-life page](/half-life).

## The CJC-1295 stack and reconstitution questions

Community protocols pairing ipamorelin with CJC-1295 — including "how much should I take" and "how to reconstitute 5mg" questions — have no peer-reviewed human dosing basis and are not given here as numbers to follow. The pharmacological rationale for co-administering a GHRP and a GHRH analog is real and documented [9][11]; a validated human dose for the combination is not. On handling: ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, and reconstituted solution is typically kept refrigerated. These are general peptide-handling notes from the research-supply literature — not a clinical preparation instruction, and not a dose.

---

A safety-led readout of the ipamorelin record — the reported side effects, the water-retention question, and the lone failed human trial logged first, with the long-term-safety line left openly blank; no clinic behind the console and nothing here dosed, prescribed, or sold.